ALA 104
Alternative Names: ALA-104; DKK1-CAR-iNKTLatest Information Update: 17 Mar 2023
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Arovella Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 17 Mar 2023 Early research in Non-small cell lung cancer in Australia (Parenteral) (Arovella Therapeutics pipeline; March 2023)
- 17 Mar 2023 Early research in Pancreatic cancer in Australia (Parenteral) (Arovella Therapeutics pipeline; March 2023)
- 17 Mar 2023 Early research in Triple-negative-breast-cancer in Australia (Parenteral) (Arovella Therapeutics pipeline; March 2023)